Clinical Trials Logo

Clinical Trial Summary

Sepsis is a life-threatening condition, caused by a systemic infection. It is particularly dangerous in already fragile populations and needs to be identified quickly to be treated as fast as possible, as discussed during the 2016 sepsis consensus and highlighted by the 2021 Surviving Sepsis Campaign. Yet, while there are scores to quickly identify patients who are at an increased risk of mortality (namely quick-SOFA, q-SOFA), these scores are also highly unspecific and cannot guarantee an adequate risk stratification. Therefore, it would be extremely valuable to further stratify mortality risk in patients who present to the emergency medical evaluation, especially those who present with stable hemodynamics but are at increased risk of decompensation during hospital stay. Furthermore, in the emergency room, it is sometimes impossible to re-evaluate patients regularly, thus, it would be important to immediately identify high-risk patients. Unfortunately, at the moment, there is no consensus. Through this study, the investigators will try to identify ultrasound parameters and biochemical markers which can be obtained during the first visit in the emergency room (ER) and that allow a quick risk stratification of patients with sepsis. The rationale of this study is to improve early identification of septic patients who are at risk of rapid deterioration in the course of their permanence in the ER and the hospital wards in general. The investigators selected a number of clinical, laboratory and bedside ultrasound parameters which have been previously shown to be correlated with mortality in sepsis, and will seek to identify which among these parameters best correlates with prognosis when acquired in the very first minutes of a patient's arrival in the ER. The objective would be to analyse these parameters and eventually to propose a new early sepsis score which might help the emergency physician to better tailor its efforts and clinical resources to the most sick patients.


Clinical Trial Description

The investigators propose a multicenter, prospective, observational study which will take place between January 2023 until the pre-specified target number of 400 patients is reached, in any case within 1 year, in three major urban, teaching Hospitals. At the end of the enrolling phase, data analysis and conclusion of the study will occur within 6 months. These patients will undergo a regular emergency room (ER) visit, during which a venous blood gas and a bedside ultrasound will be obtained, along with the collection of anamnestic and clinical parameters. All of these procedures normally take place in the first medical evaluation in the ER, therefore no unnecessary procedures or harm to patients will take place. The data which will be obtained during the first medical visit include: Anamnestic and demographic data: - Age; - Sex; - History of hypertension, diabetes, congestive heart failure, chronic lung disease, chronic kidney failure, severe immunosuppression, cancer; - Infective source, if known or suspected. Vital parameters: - Glasgow Coma Scale (GCS) and AVPU scale; - Systolic, diastolic and mean arterial blood pressure; - Heart and respiratory rate; - Body temperature; - Capillary refill time (CRT); - Peripheral oxygen saturation and oxygen supplementation if present. Venous blood gas analysis: - pH; - glucose; - lactate; - hemoglobin; - sodium and potassium. Bedside ultrasound examination: - inferior vena cava distensibility through visual gestalt; - global left ventricular contractility through visual gestalt; - mitral annular plane systolic excursion (MAPSE), obtained through apical 4-chamber view. All the above mentioned data will be obtained and reported in a specific module and subsequently added to the database. Following the first medical visit, patients will prosecute their clinical course with diagnostic and therapeutic strategies as chosen by the attending emergency physicians. No additional maneuvers will take place as far as study procedures are concerned. After a week from the enrollment, two physicians responsible for the study procedures (L.F. and G.T.) will manually extract clinical and laboratory data concerning the enrolled patients from the digital Health System softwares of the involved Hospitals. Data concerning death during hospital stay, ICU or regular ward admission, laboratory values, eventual positivity of blood culture, etc will be obtained and added to the study database. The data which will be obtained at a week from enrollment are: - Patient outcome: mortality, ICU or general ward admission; - Results of blood cultures or other cultures from relevant specimens, if available; - Results of blood tests performed during the first evaluation in the ER, including: white blood cell count (WBC), hematocrit, creatinine, C-reactive protein (CRP), Procalcitonin. The last set of data concerning mortality will be obtained at 30 days, whether in-hospital (through the electronic hospital record) or out-of-hospital by telephone call. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05787184
Study type Observational
Source Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Contact Maurizio Gabrielli, Dr.
Phone 06-30153150
Email maurizio.gabrielli@policlinicogemelli.it
Status Recruiting
Phase
Start date January 1, 2023
Completion date June 1, 2024

See also
  Status Clinical Trial Phase
Active, not recruiting NCT05095324 - The Biomarker Prediction Model of Septic Risk in Infected Patients
Completed NCT02714595 - Study of Cefiderocol (S-649266) or Best Available Therapy for the Treatment of Severe Infections Caused by Carbapenem-resistant Gram-negative Pathogens Phase 3
Completed NCT03644030 - Phase Angle, Lean Body Mass Index and Tissue Edema and Immediate Outcome of Cardiac Surgery Patients
Completed NCT02867267 - The Efficacy and Safety of Ta1 for Sepsis Phase 3
Completed NCT04804306 - Sepsis Post Market Clinical Utility Simple Endpoint Study - HUMC
Recruiting NCT05578196 - Fecal Microbial Transplantation in Critically Ill Patients With Severe Infections. N/A
Terminated NCT04117568 - The Role of Emergency Neutrophils and Glycans in Postoperative and Septic Patients
Completed NCT03550794 - Thiamine as a Renal Protective Agent in Septic Shock Phase 2
Completed NCT04332861 - Evaluation of Infection in Obstructing Urolithiasis
Completed NCT04227652 - Control of Fever in Septic Patients N/A
Enrolling by invitation NCT05052203 - Researching the Effects of Sepsis on Quality Of Life, Vitality, Epigenome and Gene Expression During RecoverY From Sepsis
Terminated NCT03335124 - The Effect of Vitamin C, Thiamine and Hydrocortisone on Clinical Course and Outcome in Patients With Severe Sepsis and Septic Shock Phase 4
Recruiting NCT04005001 - Machine Learning Sepsis Alert Notification Using Clinical Data Phase 2
Completed NCT03258684 - Hydrocortisone, Vitamin C, and Thiamine for the Treatment of Sepsis and Septic Shock N/A
Recruiting NCT05217836 - Iron Metabolism Disorders in Patients With Sepsis or Septic Shock.
Completed NCT05018546 - Safety and Efficacy of Different Irrigation System in Retrograde Intrarenal Surgery N/A
Completed NCT03295825 - Heparin Binding Protein in Early Sepsis Diagnosis N/A
Not yet recruiting NCT06045130 - PUFAs in Preterm Infants
Not yet recruiting NCT05361135 - 18-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in S. Aureus Bacteraemia N/A
Not yet recruiting NCT05443854 - Impact of Aminoglycosides-based Antibiotics Combination and Protective Isolation on Outcomes in Critically-ill Neutropenic Patients With Sepsis: (Combination-Lock01) Phase 3